President, Doramaxx Consulting
Emil W. Ciurczak, founder of Doramaxx Consulting, has almost 50 years’ experience in the pharmaceutical industry, performing method development. He has worked on pre-formulation studies, pilot plant scale-ups, as well as final product and stability indicating assay development. In 1983, he intro-duced NIRS to pharmaceutical applications (initially, for raw materials qualification). He was the first to report on polymorphism, optical isomer purity, blend uniformity, and particle size measured by NIRS. He has consulted for several NIR instrument companies, has published over seventy-five articles in refereed journals, over 300 magazine columns, and presented nearly 250 technical papers.
He is Contributing Editor for Pharmaceutical Manufacturing and Contract Pharma magazines, has written several texts and chapters on NIR applications to life sciences: “Handbook of NIR Analysis” (1st, 2nd, and 3rd ed. 4th in press), “Pharmaceutical and Medical Applications of NIRS” (1st and 2nd ed.), “Molecular Spectroscopy Workbench,” and numerous chapters. Emil is a consultant in the field of NIR and holds patents for NIR-based devices and software. He consults with pharmaceutical companies, instrument manufacturers, the FDA (PAT sub-committee, Validation), and works with the USP spectroscopy Expert group.
- Philadelphia, PA | Thursday, October 11, 2018 | Friday, October 12, 2018
View Details | Register